Expert Ratings For Halozyme Therapeutics

Loading...
Loading...

Halozyme Therapeutics HALO has been analyzed by 7 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.

The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.

Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish
Total Ratings 5 2 0 0 0
Last 30D 1 0 0 0 0
1M Ago 3 0 0 0 0
2M Ago 0 0 0 0 0
3M Ago 1 2 0 0 0

Insights from analysts' 12-month price targets are revealed, presenting an average target of $53.71, a high estimate of $72.00, and a low estimate of $50.00. Witnessing a positive shift, the current average has risen by 11.9% from the previous average price target of $48.00.

Diving into Analyst Ratings: An In-Depth Exploration

A clear picture of Halozyme Therapeutics's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target
Mitchell Kapoor HC Wainwright & Co. Maintains Buy $50.00 -
Mitchell Kapoor HC Wainwright & Co. Maintains Buy $50.00 -
Mitchell Kapoor HC Wainwright & Co. Maintains Buy $50.00 -
Robert Wasserman Benchmark Maintains Buy $50.00 -
Brendan Smith TD Cowen Announces Outperform $54.00 -
Jason Butler JMP Securities Maintains Market Outperform $72.00 -
Mitchell Kapoor HC Wainwright & Co. Raises Buy $50.00 $48.00

Key Insights:

  • Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Halozyme Therapeutics. This insight gives a snapshot of analysts' perspectives on the current state of the company.
  • Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Halozyme Therapeutics compared to the broader market.
  • Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Halozyme Therapeutics's stock. This examination reveals shifts in analysts' expectations over time.

Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Halozyme Therapeutics's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.

Stay up to date on Halozyme Therapeutics analyst ratings.

Unveiling the Story Behind Halozyme Therapeutics

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.

Halozyme Therapeutics: A Financial Overview

Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.

Revenue Growth: Halozyme Therapeutics's remarkable performance in 3 months is evident. As of 31 December, 2023, the company achieved an impressive revenue growth rate of 26.75%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: Halozyme Therapeutics's net margin excels beyond industry benchmarks, reaching 37.12%. This signifies efficient cost management and strong financial health.

Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 51.29%, the company showcases effective utilization of equity capital.

Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 4.71%, the company showcases effective utilization of assets.

Debt Management: Halozyme Therapeutics's debt-to-equity ratio surpasses industry norms, standing at 17.89. This suggests the company carries a substantial amount of debt, posing potential financial challenges.

The Core of Analyst Ratings: What Every Investor Should Know

Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.

Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst RatingsBZI-AAR
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...